IndustryCompany release

RenovoRx Q3 revenue passes $1m as RenovoCath customer base reaches 26 cancer centres

🇺🇸 RenovoRx, Inc. (RNXT) · Thu 05 Nov 2026

The US device company reported third-quarter revenue of $1.07m, held its 2026 guidance, and confirmed full enrolment in its Phase III TIGeR-PaC pancreatic cancer trial.

RenovoRx reported third-quarter 2026 results on 5 November, with revenue of $1.07m, up from $266,000 in the same period a year earlier. The company attributed the increase to commercial uptake of RenovoCath, its FDA-cleared drug-delivery device.

The number of active cancer centre customers grew to 26. RenovoRx maintained its full-year 2026 revenue guidance at $3.75m to $4.25m.

On the clinical side, the company reported full enrolment in the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. Top-line data are expected in the second half of 2027.

RenovoRx also said the first patient has been treated in an investigator-initiated neoadjuvant study at the University of Vermont. No further details on that study were provided in the material available.

What it means for your team

  • Market-access teams can note that a device-led oncology delivery product is gaining commercial traction in US cancer centres, with 26 active customers reported.
  • Regulatory and clinical teams should watch for TIGeR-PaC top-line data, expected in the second half of 2027, now that enrolment is complete.
  • The University of Vermont neoadjuvant study signals investigator-led exploration of RenovoCath beyond the company's own pivotal programme.

Company's press release (SEC filing): RenovoRx, Inc. ↗

Article written by VigiEye from the official source (RenovoRx, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →